Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%
This article was originally published in The Gray Sheet
Executive Summary
A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.